Anupam Rasayan Q1 FY27 Earnings Call — Analysis (NSE: ANURAS)
Anupam Rasayan starts FY27 with 36% revenue growth, global-first ETFA flow-chemistry commercialization, and progress on Bliss acquisition
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Consolidated total income ₹668 Cr ( +36% YoY ) . New guidance — FY27 organic revenue growth fy27 25% plus or minus a couple of percentage points . New story: Diversification beyond agrochemicals .
Results
Consolidated revenue ₹655 Cr, +36% YoY; EBITDA ₹175 Cr, +35% YoY; margin stable at 26%; PAT ₹51 Cr, +6% YoY
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated total income | ₹668 Cr | +36% | yoy · Q1FY27 |
| Revenue from operations | ₹655 Cr | +36% | yoy · Q1FY27 |
| Consolidated EBITDA | ₹175 Cr | +35% | yoy · Q1FY27 |
| Consolidated EBITDA margin | 26% | +stable | yoy · Q1FY27 |
| PAT | ₹51 Cr | +6% | yoy · Q1FY27 |
| Cash profit | ₹64 Cr | yoy · Q1FY27 · Q1FY26 ₹56 Cr | |
| Jayhawk revenue contribution | 20-22% (₹145 Cr approx.) | point_in_time · Q1FY27 · of consolidated Q1FY27 revenue | |
| Jayhawk EBITDA margin | 19-20% | point_in_time · Q1FY27 · Jayhawk stand-alone | |
| Cumulative signed LOI and contracts potential | ₹18,000 Cr | point_in_time · Q1FY27 · as of Aug 2026, over respective tenures |
Guidance
FY27 organic revenue growth guided at ~25% with additional 10-15% from Jayhawk, consolidated EBITDA margin 22-24%
What management committed to
- Anupam Rasayan's organic revenue growth in FY27 will be 25% plus or minus a couple of percentage points. — 25% plus or minus a couple of percentage points, FY27
- With the full-year consolidation of Jayhawk, consolidated revenue will see an additional 10-15% growth in FY27 over organic growth. — additional 10-15%, FY27
- Consolidated EBITDA margin will be in the range of 22-24%. — 22-24%, FY27
- Standalone EBITDA margin will be in the range of 24-26%. — 24-26%, FY27
- Capex for the existing Anupam platform will be around ₹70-80 crores in the near term. — ₹70-80 Cr, FY27
- The Bliss GVS acquisition transaction will be consummated in the first half of September 2026. — first half of September 2026
- Commercialization of the product under the BASQUEVOLT LoI will begin during FY27, specifically in the second half. — FY27
- Anupam Rasayan aims to capture 5-10% of the $500 Mn ETFA market initially, and eventually 15-30%. — 5-10% initially, 15-30% eventually
- Bliss GVS capacity utilization will improve from ~30% to 60-70% over the next 2-3 years. — 60-70%, FY29
- Contribution from the order book will be around 25% of consolidated revenue in FY27, rising to ~30% subsequently. — ~25% in FY27, ~30% subsequently, FY27
- Anupam will not need to provide funding support to Jayhawk for capex going forward, as Jayhawk is unlevered and cash-rich. — going forward
Key themes
Strategic transformation through diversification and acquisitions
How the narrative shifted
- Diversification beyond agrochemicals: Management positions the shift towards pharma, performance materials, electronics, and EV as a structural transformation reducing reliance on agro and upgrading the mix.
- Acquisition-driven platform buildout: Jayhawk provides US manufacturing/CDMO foothold; Bliss adds formulations and regulated pharma platform; Tanfac gives backward integration; the narrative is of a synergistic multi-platform specialty chemicals house.
- Flow chemistry and fluorination moat: Global-first ETFA flow-chemistry commercialization is showcased as proof of deep technological capability that will unlock cost advantages, safety, and new high-value business.
- Capex cycle completion and capital discipline: Management emphasizes that the major capex cycle is over, future spend will be selective and small, signaling a shift toward improved free cash generation and working capital focus.
- Semiconductor and next-gen applications: bullish
Operational commentary
- Commercialized Ethyl Trifluoroacetate (ETFA) using flow chemistry—first company globally to do so; strengthens fluorination expertise
- Signed Letter of Intent with BASQUEVOLT for long-term supply with total potential value of ~$300 Mn over 10 years; commercialization expected in H2 FY27
- Commercialized 1 new pharma molecule and 2 new performance materials molecules in Q1; pipeline of 65+ pharma & polymer molecules in R&D/pilot
- Jayhawk integration progressing; first full year of consolidation; contributes ~22% of Q1 revenue; Bain & Co. engaged for synergy PMO capturing semicon, defense, performance materials crossover
- Bliss GVS acquisition: SEBI approval received, open offer concluded, expected to close by mid-September 2026; platform adds 62 molecules (48+ regulated markets) and formulations capability
- Major capex cycle completed; no significant capex for existing Anupam platform in near term; future capex indicated at ₹70–80 Cr annually
- Semiconductor traction accelerating across Anupam and Jayhawk; Jayhawk already earns meaningful revenue from semicon; Anupam in commercial validation phase for semicon products
- Working capital remained stable; management expects improvement during the year supported by diversified mix and tighter receivables/inventory management
Analyst Q&A
Q. Update on HFC-32 quota for Tanfac
Addressed by Tanfac management in their call; we remain confident with Tanfac management's estimates and plans.
Q. Timeline for Bliss CDMO ramp-up
They are a listed entity, we have not consummated the transaction; please wait for a quarter more.
Q. Status of API plant acquisition
Continue to explore; once Bliss acquisition is consummated we will work with Bliss management to evaluate any acquisitions together.
Q. Semiconductor product approvals, commercialization and revenue scale-up timeline
Jayhawk has reasonable semicon revenue; Anupam in commercial validation process; no specific numbers or timelines given.
Research and educational content only. Not investment advice.